Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis

Table 2 Crude and Adjusted Prostate Cancer Risk Estimates

			Cs/Co^a	Crude OR^b	95% CI^c	Adjusted OR^d	95% CI^c
2OHE1
	*1st tertile*	*≤ 0.21*	10/37	1	-	-	-
	*2nd tertile*	*0.21 - 2.26*	9/37	0.90	0.33 -2.47	0.90	0.32-2.46
	*3rd tertile*	*> 2.26*	7/36	0.72	0.25 -2.10	0.69	0.23-2.03
	*trend*			0.85	0.50-1.44	0.83	0.49-1.42
	*P for trend*			0.55		0.50
16OHE1
	*1st tertile*	*≤ 61.84*	7/37	1	-	-	-
	*2nd tertile*	*61.84 - 158.74*	7/37	1.00	0.32 - 3.13	1.00	0.32-3.13
	*3rd tertile*	*>158.74*	12/36	1.76	0.62 - 4.98	1.73	0.58-5.14
	*trend*			1.35	0.80-2.30	1.33	0.76-2.33
	*P for trend*			0.26		0.31
2OHE1/16OHE1
	*1st tertile*	*≤ 0,31*	11/37	1	-		-
	*2nd tertile*	*0.31-1.64*	9/37	0.82	0.30-2.21	0.80	0.30-2.17
	*3rd tertile*	*> 1.64*	6/36	0.56	0.19 - 1.68	0.57	0.19-1.71
	*trend*			0.75	0.44-1.29	0.76	0.44-1.30
	*P for trend*			0.30		0.31

ISSN: 1756-9966